TNF-Alpha Fusion Molecules for Selective TNFR2 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory diseases and disorders, such as inflammatory bowel disease and rheumatoid arthritis, lack specificity in targeting TNFR2, leading to inadequate activation and stabilization of regulatory T cells, which are crucial for immune regulation.
Innovation Solution
Development of TNF-alpha variants and fusion molecules that specifically bind to TNFR2 with high affinity, selectively activating TNFR2 and enhancing the stability and suppressive function of regulatory T cells, using engineered polypeptides with specific amino acid sequences and linkers to enhance stability and bioactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat inflammatory diseases, then they can reduce inflammation, but they lack specificity in targeting TNFR2 leading to inadequate activation of regulatory T cells
Solution Approach 1:
The patent applies local quality by engineering TNF-alpha variants with specific amino acid substitutions (e.g., E139Q, E139A, E139K) that create localized changes in the protein structure. These localized modifications enable the variant to specifically bind to TNFR2 while maintaining the ability to activate regulatory T cells, thus resolving the contradiction between specificity and activation efficacy
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequence parameters of TNF-alpha to create variants with altered binding properties. The specific substitutions at positions 139, 143, and 145 change the molecular parameters of the protein, enabling selective TNFR2 binding while preserving immunomodulatory function
2Reliability
If TNF-alpha variants with high TNFR2 affinity are developed, then specificity and activation of regulatory T cells improve, but the molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the TNF-alpha protein into functional domains and making targeted substitutions in specific regions (positions 139-145). This segmented approach allows precise modification of binding affinity without requiring complete redesign of the entire molecular structure, thus managing complexity while achieving high specificity
Solution Approach 2:
The patent achieves universality by creating TNF-alpha variants that maintain multiple functions: specific TNFR2 binding, regulatory T cell activation, and anti-inflammatory activity. The variants serve as multi-functional molecules that combine targeting specificity with immunomodulatory efficacy, reducing the need for separate therapeutic agents
3Reliability
If fusion molecules are engineered to enhance stability and bioactivity, then therapeutic efficacy improves, but the manufacturing complexity increases
Solution Approach 1:
The patent applies merging by fusing TNF-alpha variants with Fc domains to create fusion molecules. This combination enhances therapeutic efficacy through improved stability, extended half-life, and increased bioactivity. The fusion approach consolidates multiple beneficial properties into a single molecule, simplifying the therapeutic regimen despite increased molecular complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TNF-alpha variants and fusion molecules effectively activate TNFR2, stabilizing regulatory T cells, thereby improving immune regulation and reducing inflammation in inflammatory diseases.
Implementation Method 1
TNF-alpha variants comprising a polypeptide that specifically binds to TNFR2
Data Source
AI summary
The present disclosure relates to TNF-alpha variants and TNF-alpha variant fusion molecules and therapeutic uses of such thereof.